HARMONY demonstrates the power of Big Data analytics to inform personalized medicine in blood cancer. By pooling data of thousands of patients, HARMONY researchers will be able to study combinations of prognostic factors, for instance minimal residual disease in combination with genetic profile. This may allow researchers to more precisely predict clinical course and drug response, enabling physicians to rapidly select the most promising and least toxic treatment for a particular patient.
by HARMONY Partners: Dr. Guillermo Sanz, Head of the Clinical Hematology Section at Hospital Universitario La Fe from Valencia and HARMONY Co-Chair and Dr. Jesús María Hernández Rivas, specialist of the Hematology Service of the University Hospital of Salamanca and HARMONY Coordinator.
by HARMONY Partners: Professor Richard Rosenquist Brandell, Professor of Clinical Genetics at Karolinska Institutet and director of Genomic Medicine Sweden; Professor Lars Bullinger, Director of the Medical Department of Hematology, Oncology, and Tumorimmunology of the Charité Universitätsmedizin Berlin; Professor Kimmo Porkka, Head Hematology Division/HUCH of the University of Helsinki; Professor Caroline Heckman, Research Director at the Institute for Molecular Medicine Finland (FIMM) of the University of Helsinki.
The Patient Cluster and their patient communities are consistently involved in the definition of outcomes, the design of Research Projects and the information of patients. In addition the Patient Cluster also make sure that there is a reliable bi-directional flow of information within and outside of the Alliance. For the first time in a major research project, the patient community sits at the table as truly equal partners to researchers, industry and regulators.
Listen to Tamás Bereczky from HARMONY Partner Leukanet
Listen to Solène Clavreul, Myeloma Patients Europe.
Receive the latest news. Click here to subscribe!